1. ZhengYH, JeangKT, TokunagaK (2012) Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology 9: 112.
2. DuggalNK, EmermanM (2012) Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol 12: 687–695.
3. KoTP, LinJJ, HuCY, HsuYH, WangAH, et al. (2003) Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution. J Biol Chem 278: 19111–19117.
4. BishopKN, HolmesRK, SheehyAM, MalimMH (2004) APOBEC-mediated editing of viral RNA. Science 305: 645–645.
5. MangeatB, TurelliP, CaronG, FriedliM, PerrinL, et al. (2003) Broad antiretroviral defense by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99–103.
6. HarrisRS, SheehyAM, CraigHM, MalimMH, NeubergerMS (2003) DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol 4: 641–643.
7. BishopKN, HolmesRK, SheehyAM, DavidsonNO, ChoSJ, et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14: 1392–1396.
8. BealeRC, Petersen-MahrtSK, WattIN, HarrisRS, RadaC, et al. (2004) Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol 337: 585–596.
9. BishopKN, VermaM, KimEY, WolinskySM, MalimMH (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231.
10. IwataniY, ChanDS, WangF, MaynardKS, SugiuraW, et al. (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucl Acids Res 35: 7096–7108.
11. WangX, AoZ, ChenL, KobingerG, PengJ, et al. (2012) The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J Virol 86: 3777–3786.
12. SheehyAM, GaddisNC, MalimMH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404–1407.
13. StopakK, de NoronhaC, YonemotoW, GreeneWC (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12: 591–601.
14. WiegandHL, DoehleBP, BogerdHP, CullenBR (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 23: 2451–2458.
15. DesimmieBA, Delviks-FrankenberrryKA, BurdickRC, QiD, IzumiT, et al. (2014) Multiple APOBEC3 Restriction Factors for HIV-1 and One Vif to Rule Them All. J Mol Biol 426: 1220–1245.
16. SchrofelbauerB, ChenD, LandauNR (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 101: 3927–3932.
17. MarianiR, ChenD, SchrofelbauerB, NavarroF, KonigR, et al. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: 21–31.
18. BogerdHP, WiegandHL, DoehleBP, LuedersKK, CullenBR (2006) APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucl Acids Res 34: 89–95.
19. MuckenfussH, HamdorfM, HeldU, PerkovicM, LowerJ, et al. (2006) APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem 281: 22161–22172.
20. ChenH, LilleyCE, YuQ, LeeDV, ChouJ, et al. (2006) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 16: 480–485.
21. PengG, Greenwell-WildT, NaresS, JinW, LeiKJ, et al. (2007) Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110: 393–400.
22. AguiarRS, LovsinN, TanuriA, PeterlinBM (2008) Vpr.A3A chimera inhibits HIV replication. J Biol Chem 283: 2518–2525.
23. KoningFA, GoujonC, BaubyH, MalimMH (2011) Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J Virol 85: 13448–13452.
24. BergerG, DurandS, FargierG, NguyenXN, CordeilS, et al. (2011) APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog 7: e1002221.
25. OomsM, KrikoniA, KressAK, SimonV, MunkC (2012) APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J Virol 86: 6097–6108.
26. ThielenBK, McNevinJP, McElrathMJ, HuntBV, KleinKC, et al. (2010) Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem 285: 27753–27766.
27. RibeiroAC, Maia e SilvaA, Santa-MartaM, PomboA, Moniz-PereiraJ, et al. (2005) Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol 79: 823–833.
28. JonssonSR, LaRueRS, StengleinMD, FahrenkrugSC, AndresdottirV, et al. (2007) The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS One 2: e893.
29. LeeJ, ChoiJY, LeeHJ, KimKC, ChoiBS, et al. (2011) Repression of porcine endogenous retrovirus infection by human APOBEC3 proteins. Biochem Biophys Res Commun 407: 266–270.
30. GroomHC, YapMW, GalaoRP, NeilSJ, BishopKN (2010) Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci USA 107: 5166–5171.
31. TakedaE, Tsuji-KawaharaS, SakamotoM, LangloisMA, NeubergerMS, et al. (2008) Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol 82: 10998–11008.
32. LowA, OkeomaCM, LovsinN, de las HerasM, TaylorTH, et al. (2009) Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virol 385: 455–463.
33. OkeomaCM, LovsinN, PeterlinBM, RossSR (2007) APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445: 927–930.
34. NarvaizaI, LinfestyDC, GreenerBN, HakataY, PintelDJ, et al. (2009) Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog 5: e1000439.
35. TurelliP, MangeatB, JostS, VianinS, TronoD (2004) Inhibition of hepatitis B virus replication by APOBEC3G. Science 303: 1829.
36. NguyenDH, GummuluruS, HuJ (2007) Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 81: 4465–4472.
37. BonvinM, AchermannF, GreeveI, StrokaD, KeoghA, et al. (2006) Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43: 1364–1374.
38. VartanianJP, GuetardD, HenryM, Wain-HobsonS (2008) Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320: 230–233.
39. SuspeneR, AynaudMM, KochS, PasdeloupD, LabetoulleM, et al. (2011) Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J Virol 85: 7594–7602.
40. CullenBR (2006) Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 80: 1067–1076.
41. OkeomaCM, PetersenJ, RossSR (2009) Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J Virol 83: 3029–3038.
42. OkeomaCM, LowA, BailisW, FanHY, PeterlinBM, et al. (2009) Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection. J Virol 83: 3486–3495.
43. OkeomaCM, HuegelAL, LingappaJ, FeldmanMD, RossSR (2010) APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe 8: 534–543.
44. SantiagoML, MontanoM, BenitezR, MesserRJ, YonemotoW, et al. (2008) Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321: 1343–1346.
45. LangloisMA, KemmerichK, RadaC, NeubergerMS (2009) The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J Virol 83: 11550–11559.
46. Sanchez-MartinezS, AloiaAL, HarvinD, MirroJ, GorelickRJ, et al. (2012) Studies on the restriction of murine leukemia viruses by mouse APOBEC3. PLoS ONE 7: e38190.
47. MacMillanAL, KohliRM, RossSR (2013) APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J Virol 87: 4808–4817.
48. RulliSJJr, MirroJ, HillSA, LloydP, GorelickRJ, et al. (2008) Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol 82: 6566–6575.
49. HarrisRS, BishopKN, SheehyAM, CraigHM, Petersen-MahrtSK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803–809.
50. KobayashiM, Takaori-KondoA, ShindoK, AbuduA, FukunagaK, et al. (2004) APOBEC3G targets specific virus species. J Virol 78: 8238–8244.
51. Goila-GaurR, KhanMA, MiyagiE, KaoS, StrebelK (2007) Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 4: 61.
52. RulliK, LenzJ, LevyLS (2002) Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus. J Virol 76: 2363–2374.
53. ArdavinC, FerreroI, AzcoitiaI, AnjuereF, DiggelmanH, et al. (1999) B cell response after MMTV infection: extrafollicular plasmablasts represent the main infected population and can transmit viral infection. J Immunol 162: 2538–2545.
54. DzurisJL, GolovkinaTV, RossSR (1997) Both T and B cells shed infectious mouse mammary tumor virus. J Virol 71: 6044–6048.
55. FinstadSL, RosenbergN, LevyLS (2007) Diminished potential for B-lymphoid differentiation after murine leukemia virus infection in vivo and in EML hematopoietic progenitor cells. J Virol 81: 7274–7279.
56. CourregesMC, BurzynD, NepomnaschyI, PiazzonI, RossSR (2007) Critical role of dendritic cells in mouse mammary tumor virus in vivo infection. J Virol 81: 3769–3777.
57. BalkowS, KruxF, LoserK, BeckerJU, GrabbeS, et al. (2007) Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naive T cells, and favors expansion of regulatory T cells. Blood 110: 3949–3958.
58. StavrouS, NittaT, KotlaS, HaD, NagashimaK, et al. (2013) Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex. Proc Natl Acad Sci USA 110: 9078–9083.
59. NewmanEN, HolmesRK, CraigHM, KleinKC, LingappaJR, et al. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15: 166–170.
60. BishopKN, HolmesRK, MalimMH (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 80: 8450–8458.
61. HolmesRK, KoningFA, BishopKN, MalimMH (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation: Comparisons with APOBEC3G. J Biol Chem 282: 2587–2595.
62. HarelJ, RassartE, JolicoeurP (1981) Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virus. Virol 110: 202–207.
63. RossSR (1997) Mouse mammary tumor virus and the immune system. Adv Pharmacol 39: 21–46.
64. SzymczakAL, VignaliDA (2005) Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther 5: 627–638.
65. AnP, BleiberG, DuggalP, NelsonG, MayM, et al. (2004) APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 78: 11070–11076.
66. ReddyK, WinklerCA, WernerL, MlisanaK, Abdool KarimSS, et al. (2010) APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 24: 195–204.
67. BizinotoMC, LealE, DiazRS, JaniniLM (2011) Loci polymorphisms of the APOBEC3G gene in HIV type 1-infected Brazilians. AIDS Res Hum Retroviruses 27: 137–141.
68. BrowneEP, LittmanDR (2008) Species-specific restriction of apobec3-mediated hypermutation. J Virol 82: 1305–1313.
69. RulliSJJr, MirroJ, HillSA, LloydP, GorelickRJ, et al. (2008) Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol 82: 6566–6575.
70. SheehyAM, GaddisNC, MalimMH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404–1407.
71. StopakK, de NoronhaC, YonemotoW, GreeneWC (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12: 591–601.
72. KriskoJF, Martinez-TorresF, FosterJL, GarciaJV (2013) HIV restriction by APOBEC3 in humanized mice. PLoS Pathog 9: e1003242.
73. TurelliP, Liagre-QuazzolaA, MangeatB, VerpS, JostS, et al. (2008) APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice. J Virol 82: 6585–6590.
74. LandryS, NarvaizaI, LinfestyDC, WeitzmanMD (2011) APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep 12: 444–450.
75. SuspeneR, AynaudMM, GuetardD, HenryM, EckhoffG, et al. (2011) Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc Natl Acad Sci USA 108: 4858–4863.
76. LutzMB, KukutschN, OgilvieAL, RossnerS, KochF, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77–92.
77. FanH, ChuteH, ChaoE, FeuermanM (1983) Construction and characterization of Moloney murine leukemia virus mutants unable to synthesize glycosylated gag polyprotein. Proc Natl Acad Sci USA 80: 5965–5969.
78. PortisJL, McAteeFJ, KaymanSC (1992) Infectivity of retroviral DNA in vivo. J Acquir Immune Defic Syndr 5: 1272–1273.
79. RassaJC, MeyersJL, ZhangY, KudaravalliR, RossSR (2002) Murine retroviruses activate B cells via interaction with Toll-like receptor 4. Proc Natl Acad Sci USA 99: 2281–2286.